ArticleJournal of acquired immune deficiency syndromes (1999)2012
Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapy.
Article in Journal of acquired immune deficiency syndromes (1999), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy.PloS one · 2013Trial
- Article
- Time of HIV diagnosis, CD4 count and viral load at antenatal care start and delivery in South Africa.PloS one · 2020Article
- Loss to follow-up from antiretroviral therapy clinics: A systematic review and meta-analysis of published studies in South Africa from 2011 to 2015.Southern African journal of HIV medicine · 2019Article
- Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa.PloS one · 2018Article
- Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.AIDS (London, England) · 2017Article
- Lost Opportunities Concerning Loss-to-Follow-up: A Response to Elul et al.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- A risk score to identify HIV-infected women most likely to become lost to follow-up in the postpartum period.AIDS care · 2016Article
- Effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.AIDS research and human retroviruses · 2013Article
- Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis.Infectious diseases in obstetrics and gynecology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePregnancy is a common indication for initiation of highly active antiretroviral therapy (HAART) in sub-Saharan Africa. Our objective was to evaluate how pregnancy at treatment initiation predicts virologic response to HAART.
methodsWe evaluated an open cohort of 9173 patients who initiated HAART between April 2004 and September 2009 in the Themba Lethu Clinic in Johannesburg, South Africa. Risk ratios were estimated using log-binomial regression; hazard ratios were estimated using Cox proportional hazards models; time ratios were estimated using accelerated failure time models. We controlled for calendar date, age, ethnicity, employment status, history of smoking, tuberculosis, WHO stage, weight, body mass index, hemoglobin, CD4 count and CD4 percent, and whether clinical care was free. Extensive sensitivity and secondary analyses were performed.
resultsDuring follow-up, 822 nonpregnant women and 70 pregnant women experienced virologic failure. In adjusted analyses, pregnancy at baseline was associated with reduced risk of virologic failure by 6 months [risk ratio 0.66, 95% confidence limits (CL): 0.35 to 1.22] and with reduced hazard of virologic failure over follow-up (hazard ratio: 0.69, 95% CL: 0.50 to 0.95). The adjusted time ratio for failure was 1.44 (95% CL: 1.13 to 1.84), indicating 44% longer time to event among women pregnant at baseline. Sensitivity analyses generally confirmed main findings.
conclusionsPregnancy at HAART initiation is not associated with increased risk of virologic failure at 6 months or during longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.